EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial.
EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial.
复制标题
DOI：
10.1038/bjc.2014.442
复制
发表时间：
2014-09-09
影响因子：
8.8
通讯作者：
Perez, E. A.
中科院分区：
文献类型：
--
作者：
Cheng, H.;Ballman, K.;Vassilakopoulou, M.;Dueck, A. C.;Reinholz, M. M.;Tenner, K.;Gralow, J.;Hudis, C.;Davidson, N. E.;Fountzilas, G.;McCullough, A. E.;Chen, B.;Psyrri, A.;Rimm, D. L.;Perez, E. A.
关键词：
Epidermal growth factor receptor (EGFR) has been hypothesised to modulate the effectiveness of anti-HER2 therapy. We used a standardised, quantitative immunofluorescence assay and a novel EGFR antibody to evaluate the correlation between EGFR expression and clinical outcome in the North Central Cancer Treatment Group (NCCTG) N9831 trial. Tissue microarrays were constructed that allowed analysis of 1365 patients randomly assigned to receive chemotherapy alone (Arm A), sequential trastuzumab after chemotherapy (Arm B) and chemotherapy with concurrent trastuzumab (Arm C). Measurement of EGFR was performed using the EGFR antibody, D38B1, on the fluorescence-based AQUA platform. The result was validated using an independent retrospective metastatic breast cancer cohort (n=130). Epidermal growth factor receptor assessed as a continuous (logarithmic transformed) variable shows an association with disease-free survival in Arm C (P=0.009) but not in Arm A or B. High EGFR expression was associated with worse outcome (Hazard ratio (HR)=2.15; 95% CI 1.28–3.60, P=0.004). Validation in a Greek metastatic breast cancer cohort showed an HR associated with high EGFR expression of 1.92 (P=0.0073). High expression of EGFR appears to be associated with decreased benefit from adjuvant concurrent trastuzumab. Since other treatment options exist for HER2-driven tumours, further validation of these data may select patients for alternative or additive therapy.
登录
查看更多内容
影响因子：
45.3
作者：
Perez, Edith A.;Romond, Edward H.;Wolmark, Norman
通讯作者：
Wolmark, Norman
影响因子：
3.8
作者：
Razis, E.;Bobos, M.;Fountzilas, G.
通讯作者：
Fountzilas, G.
影响因子：
45.3
作者：
Lenz, Heinz-Josef;Van Cutsem, Eric;Rowinsky, Eric K.
通讯作者：
Rowinsky, Eric K.
影响因子：
4.8
作者：
Xia, L;Wang, LJ;Chin, YE
通讯作者：
Chin, YE
影响因子：
10.3
作者：
Perez, Edith A.;Dueck, Amylou C.;Chen, Beiyun
通讯作者：
Chen, Beiyun